Lund, Sweden, 2013-06-03 15:10 CEST (GLOBE NEWSWIRE) --
EXINI Diagnostics AB (NASDAQ OMX First North: EXINI) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today presented Phase II retrospective follow-up data from the prostate cancer project with tasquinimod combined with BSI - evaluation (Bone Scan Index) at the scientific conference “2013 ASCO (American Society of Clinical Oncology) Annual Meeting” held in Chicago (USA).
Today Dr. Andrew J. Armstrong from the Duke Cancer Institute (Durham, NC) presented “Tasquinimod and effects on bone scan index in men with metastatic castration-resistant prostate cancer (mCRPC): results of retrospective follow up of a randomized phase 2 placebo-controlled trial.”
Using EXINIs automated software for analysis of the BSI, a quantitative measure of tumor burden in bone, the relation of the BSI with other prognostic biomarkers and overall survival were analyzed in a data set from the previously concluded Phase II tasquinimod clinical study.
“These results show that BSI can be a valuable and more objective radiologic assessment in trials of men with metastatic castration-resistant prostate cancer, and is clearly associated with prognosis and disease burden. Tasquinimod had a favorable impact on the BSI over time, confirming our original findings in the randomized phase 2 trial. The ability to obtain objective measures of bone metastases can help fuel drug development in this disease, where current bone scan assessments are often misclassified and very subjective”, says principal author Andrew Armstrong, MD ScM, Associate Professor of Medicine and Surgery at the Duke Cancer Institute and a member of the Duke Prostate Center.
Helén Tuvesson, CSO Active Biotech, said: “This type of innovative collaborations, utilizing novel technologies, may be most valuable in the future development of tasquinimod”.
Magnus Aurell, CEO EXINI Diagnostics: ”The development of new medical drugs is very important for our products and these new published results are very positive for our imaging biomarker BSI. Equally important for us is the continuous use of our products in clinical practice, where the prediction of efficient treatment on an individual basis often can be difficult. EXINI boneBSI is well suited for clinical use because the software can easily be used in all kinds of hospitals and by many different users.”
For more detailed information, please see www.asco.org and www.activebiotech.com.
For more information, please contact:
Magnus Aurell, CEO
Phone: +46 46 286 54 25
E-mail: magnus.aurell@exini.com
About EXINI Diagnostics AB (publ)
EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of radiology images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. The company was founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock market NASDAQ OMX First North and has about 500 shareholders. Principal owner is Bo Håkansson. Thenberg & Kinde Fondkomission AB acts as Certified Adviser.
________________________________________________________________________
EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden
Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com
